Functionalized stilbene derivatives as improved vascular targeting agents
USRE45907E1 · kind E1 · reissue
0Cited by
12References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 13, 2014 |
| Grant date | Mar 1, 2016 |
| Priority date | — |
| Expiry date | Feb 13, 2034 |
Classification
- Technology area (CPC —)General
Abstract
Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.